Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Pharmacol. 2008 May 15;75(10):1893-900. doi: 10.1016/j.bcp.2007.12.018. Epub 2008 Jan 5.

New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.

Author information

  • 1Institute of Pharmacology, University of Bern, Friedb├╝hlstrasse 49, CH-3010 Bern, Switzerland. Huwiler@pki.unibe.ch

Abstract

The recent identification of a cellular balance between ceramide and sphingosine 1-phosphate (S1P) as a critical regulator of cell growth and death has stimulated increasing research effort to clarify the role of ceramide and S1P in various diseases associated with dysregulated cell proliferation and apoptosis. S1P acts mainly, but not exclusively, by binding to and activating specific cell surface receptors, the so-called S1P receptors. These receptors belong to the class of G protein-coupled receptors that constitute five subtypes, denoted as S1P(1)-S1P(5), and represent attractive pharmacological targets to interfere with S1P action. Whereas classical receptor antagonists will directly block S1P action, S1P receptor agonists have also proven useful, as recently shown for the sphingolipid-like immunomodulatory substance FTY720. When phosphorylated by sphingosine kinase to yield FTY720 phosphate, it acutely acts as an agonist at S1P receptors, but upon prolonged presence, it displays antagonistic activity by specifically desensitizing the S1P(1) receptor subtype. This commentary will cover the most recent developments in the field of S1P receptor pharmacology and highlights the potential therapeutic benefit that can be expected from these novel drug targets in the future.

PMID:
18321471
DOI:
10.1016/j.bcp.2007.12.018
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center